PMID- 35903895
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221206
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 10
DP  - 2022 Oct
TI  - Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus 
      ultraviolet A irradiation and low-dose interferon-alpha: Long-term efficacy and 
      survival according to conventional and emerging clinical endpoints.
PG  - e15737
LID - 10.1111/dth.15737 [doi]
AB  - Patients with early stage cutaneous T cell lymphoma (CTCL) usually have a benign 
      and chronic disease course, characterized by temporally response to conventional 
      skin directed therapies and intrinsic possibility to evolve. Using the 
      combination of psoralen plus ultraviolet A irradiation (PUVA) and low-dose 
      interferon-alpha (INF), the principal treatment goal is to keep confined the disease 
      to the skin, preventing disease progression. Among 87 patients with early stage 
      IA to IIA MF treated with low-dose IFN-alpha2b and PUVA in our center, complete 
      remission (CR) were reported in 70 patients (80.5%) and the overall response rate 
      (ORR) was 97.8% (n = 85), with a median time to best response to therapy of 
      5 months (range, 1-30). Among the responders, only the 8% of patients had a 
      relapse with major event. The median follow-up was 207 months (range, 6-295). 
      Survival data showed a median overall survival (OS) not reached (95% CI; 235-NR 
      months), a disease free survival (DFS) of 210 months (95% CI; 200-226 months) and 
      a median time to next treatment (TTNT) of 38.5 months (95% CI, 33-46 months). The 
      long follow up of this study verifies our preliminary results already published 
      in 2006 and confirms the efficacy of INF-PUVA combination therapy in a real world 
      setting, according conventional (OS and DFS) and emerging (TTNT) clinical 
      endpoint of treatment efficacy.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Rupoli, Serena
AU  - Rupoli S
AD  - Clinica di Ematologia, Universita Politecnica delle Marche, Ancona, Italy.
FAU - Goteri, Gaia
AU  - Goteri G
AD  - Unita di Anatomia Patologica, Ancona, Italy.
FAU - Morsia, Erika
AU  - Morsia E
AD  - Clinica di Ematologia, Universita Politecnica delle Marche, Ancona, Italy.
FAU - Torre, Elena
AU  - Torre E
AD  - Clinica di Ematologia, Universita Politecnica delle Marche, Ancona, Italy.
FAU - Giantomassi, Federica
AU  - Giantomassi F
AD  - Unita di Anatomia Patologica, Ancona, Italy.
FAU - Campanati, Anna
AU  - Campanati A
AD  - Clinica di Dermatologia, Dipartimento di scienze cliniche e molecolari, 
      Universita Politecnica delle Marche, Ancona, Italy.
FAU - Offidani, Anna Maria
AU  - Offidani AM
AD  - Clinica di Dermatologia, Dipartimento di scienze cliniche e molecolari, 
      Universita Politecnica delle Marche, Ancona, Italy.
FAU - Molinelli, Elisa
AU  - Molinelli E
AUID- ORCID: 0000-0002-7939-0026
AD  - Clinica di Dermatologia, Dipartimento di scienze cliniche e molecolari, 
      Universita Politecnica delle Marche, Ancona, Italy.
FAU - Brandozzi, Giuliano
AU  - Brandozzi G
AD  - Clinica di Dermatologia, Dipartimento di scienze cliniche e molecolari, 
      Universita Politecnica delle Marche, Ancona, Italy.
FAU - Serresi, Stefano
AU  - Serresi S
AD  - Dermatologia, INRCA/IRCCS, Ancona, Italy.
FAU - Giacchetti, Alfredo
AU  - Giacchetti A
AD  - Dermatologia, INRCA/IRCCS, Ancona, Italy.
FAU - Bugatti, Leonardo
AU  - Bugatti L
AD  - Unita di Dermatologia, Carlo Urbani Hospital, Italy.
FAU - Filosa, Giorgio
AU  - Filosa G
AD  - Unita di Dermatologia, Carlo Urbani Hospital, Italy.
FAU - Mozzicafreddo, Giorgio
AU  - Mozzicafreddo G
AD  - Dermatologia, INRCA/IRCCS, Ancona, Italy.
FAU - Simonacci, Marco
AU  - Simonacci M
AD  - Unita di Dermatologia, Carlo Urbani Hospital, Italy.
AD  - Dipartimento di Dermatologia, Macerata Hospital, Macerata, Italy.
FAU - Olivieri, Attilio
AU  - Olivieri A
AD  - Clinica di Ematologia, Universita Politecnica delle Marche, Ancona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220809
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Interferon-alpha)
RN  - KTZ7ZCN2EX (Ficusin)
SB  - IM
MH  - Ficusin/therapeutic use
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - *Lymphoma, T-Cell, Cutaneous/pathology
MH  - *Mycosis Fungoides/drug therapy/pathology/radiotherapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - PUVA Therapy/methods
MH  - Prognosis
MH  - *Skin Neoplasms/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cutaneous T-cell lymphoma
OT  - interferon-alpha
OT  - mycosis fungoides
OT  - psoralen plus ultraviolet A irradiation
EDAT- 2022/07/30 06:00
MHDA- 2022/10/05 06:00
CRDT- 2022/07/29 02:53
PHST- 2022/06/14 00:00 [revised]
PHST- 2022/03/15 00:00 [received]
PHST- 2022/07/21 00:00 [accepted]
PHST- 2022/07/30 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/07/29 02:53 [entrez]
AID - 10.1111/dth.15737 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Oct;35(10):e15737. doi: 10.1111/dth.15737. Epub 2022 Aug 9.